Analyst Consensus ?
ConsensusBuy33 ratings
Bullish1854.5%
Neutral1545.5%
Bearish00.0%
FN2 Earnings Intelligence
Cardinal Health, Inc. analyst ratings
Cardinal Health, Inc. (CAH) analyst consensus, price targets, and firm-level rating history from FN2 Research.
Analyst 52W Price Targets
$246.45Current
$53Low
$196Average
$295High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 28, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Mizuho | Outperform | Outperform | Maintain | Oct 20, 2026 |
| UBS | Buy | Buy | Maintain | Oct 16, 2026 |
| TD Cowen | Buy | Buy | Maintain | Aug 13, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Aug 13, 2026 |
| Barclays | Overweight | Overweight | Maintain | Aug 13, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Aug 12, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Aug 12, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Aug 12, 2026 |
| Citigroup | Buy | Buy | Maintain | Aug 12, 2026 |
| Baird | Outperform | Outperform | Maintain | Aug 12, 2026 |
| B of A Securities | Buy | Buy | Maintain | Jul 2, 2026 |
| Leerink Partners | Outperform | Outperform | Maintain | Aug 12, 2025 |
| Jefferies | Buy | Hold | Upgrade | Feb 5, 2025 |
| Deutsche Bank | Hold | Hold | Maintain | Nov 4, 2024 |
| Argus Research | Buy | Buy | Maintain | Sep 11, 2024 |
| Credit Suisse | Neutral | Neutral | Maintain | Jun 12, 2023 |
| Cowen & Co. | Market Perform | Market Perform | Maintain | Aug 16, 2022 |
| CFRA | Hold | Hold | Maintain | May 11, 2020 |
| Guggenheim | Neutral | Buy | Downgrade | Dec 16, 2019 |
| Argus | Hold | Buy | Downgrade | Aug 27, 2019 |
| Leerink Swann | Market Perform | Outperform | Downgrade | Nov 16, 2018 |
| RBC Capital | Perform | Sector Perform | Maintain | Sep 19, 2017 |
| Tigress Financial | Neutral | Neutral | Maintain | Apr 28, 2017 |
| William Blair | Market Perform | Outperform | Downgrade | Apr 19, 2017 |
| Needham | Hold | Hold | Maintain | Apr 4, 2017 |
| Goldman Sachs | Neutral | Buy | Downgrade | Sep 16, 2016 |
| Avondale Partners | Outperform | Market Outperform | Maintain | Apr 18, 2016 |
| Raymond James | Market Perform | Outperform | Downgrade | Jan 6, 2016 |
| FBR Capital | Outperform | Outperform | Maintain | Mar 10, 2015 |
| Bank of America | Buy | Buy | Maintain | Dec 29, 2014 |
| Sterne Agee | Buy | Neutral | Upgrade | Nov 6, 2013 |
| ISI Group | Buy | Strong Buy | Downgrade | Mar 20, 2013 |
| Lazard | Neutral | Buy | Downgrade | Mar 19, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $246.45. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Mizuho Securities | Analyst unavailable | $280 | $252.65 | +13.6% | Oct 20, 2026 |
| UBS | Kevin Caliendo | $295 | $253.71 | +19.7% | Oct 16, 2026 |
| RBC Capital | Ryan Halsted | $276 | $234.98 | +12.0% | Aug 19, 2026 |
| Barclays | Analyst unavailable | $275 | $234.16 | +11.6% | Aug 13, 2026 |
| Morgan Stanley | Analyst unavailable | $265 | $236.64 | +7.5% | Aug 12, 2026 |
| Evercore ISI | Analyst unavailable | $270 | $240.26 | +9.6% | Aug 12, 2026 |
| UBS | Analyst unavailable | $280 | $240.26 | +13.6% | Aug 12, 2026 |
| Wells Fargo | Stephen Baxter | $277 | $240.26 | +12.4% | Aug 12, 2026 |
| Mizuho Securities | Steven Valiquette | $250 | $240.26 | +1.4% | Aug 12, 2026 |
| Robert W. Baird | Eric Coldwell | $274 | $240.26 | +11.2% | Aug 12, 2026 |
| Leerink Partners | Analyst unavailable | $292 | $240.26 | +18.5% | Aug 11, 2026 |
| UBS | Analyst unavailable | $274 | $226.42 | +11.2% | Jul 20, 2026 |
| Robert W. Baird | Analyst unavailable | $248 | $195.08 | +0.6% | May 1, 2026 |
| Evercore ISI | Elizabeth Anderson | $240 | $215.13 | -2.6% | Apr 8, 2026 |
| Leerink Partners | Michael Cherny | $275 | $222.28 | +11.6% | Mar 9, 2026 |
| Barclays | Analyst unavailable | $258 | $224.82 | +4.7% | Feb 24, 2026 |
| Wells Fargo | Analyst unavailable | $256 | $225.76 | +3.9% | Feb 10, 2026 |
| Morgan Stanley | Analyst unavailable | $255 | $229.63 | +3.5% | Feb 6, 2026 |
| Robert W. Baird | Analyst unavailable | $252 | $228.78 | +2.3% | Feb 6, 2026 |
| UBS | Kevin Caliendo | $260 | $228.63 | +5.5% | Feb 6, 2026 |
| Mizuho Securities | Steven Valiquette | $235 | $227.18 | -4.6% | Feb 6, 2026 |
| Evercore ISI | Elizabeth Anderson | $260 | $227.18 | +5.5% | Feb 5, 2026 |
| Morgan Stanley | Erin Wright | $245 | $210.39 | -0.6% | Jan 29, 2026 |
| Robert W. Baird | Eric Coldwell | $250 | $211.98 | +1.4% | Jan 14, 2026 |
| Leerink Partners | Michael Cherny | $240 | $208.24 | -2.6% | Jan 13, 2026 |
| Mizuho Securities | Steven Valiquette | $222 | $201.11 | -9.9% | Jan 12, 2026 |
| Barclays | Glen Santangelo | $243 | $198.88 | -1.4% | Dec 8, 2025 |
| Mizuho Securities | Steven Valiquette | $210 | $190.22 | -14.8% | Nov 3, 2025 |
| Jefferies | Analyst unavailable | $220 | $190.22 | -10.7% | Nov 3, 2025 |
| Evercore ISI | Elizabeth Anderson | $220 | $191.29 | -10.7% | Oct 31, 2025 |
| UBS | Analyst unavailable | $220 | $192.07 | -10.7% | Oct 31, 2025 |
| Robert W. Baird | Analyst unavailable | $232 | $192.36 | -5.9% | Oct 31, 2025 |
| Argus Research | Analyst unavailable | $189 | $148.1 | -23.3% | Aug 22, 2025 |
| Leerink Partners | Michael Cherny | $186 | $146.3 | -24.5% | Aug 12, 2025 |
| Jefferies | Brian Tanquilut | $150 | $157.66 | -39.1% | Aug 12, 2025 |
| Morgan Stanley | Erin Wright | $181 | $161.41 | -26.6% | Jun 13, 2025 |
| Wells Fargo | Stephen Baxter | $179 | $155.48 | -27.4% | Jun 3, 2025 |
| Argus Research | Kristina Ruggeri | $148 | $125.17 | -39.9% | Feb 4, 2025 |
| Robert W. Baird | Eric Coldwell | $140 | $112.3 | -43.2% | Sep 23, 2024 |
| Argus Research | David Toung | $125 | $112.36 | -49.3% | Sep 11, 2024 |
| Deutsche Bank | George Hill | $119 | $107.91 | -51.7% | Aug 16, 2024 |
| Evercore ISI | Elizabeth Anderson | $115 | $107.71 | -53.3% | Aug 15, 2024 |
| Morgan Stanley | Erin Wright | $119 | $106.36 | -51.7% | Aug 15, 2024 |
| Mizuho Securities | Ann Hynes | $110 | $107.39 | -55.4% | Aug 15, 2024 |
| Robert W. Baird | Eric Coldwell | $137 | $107.33 | -44.4% | Aug 15, 2024 |
| Wells Fargo | Stephen Baxter | $101 | $106.36 | -59.0% | Aug 15, 2024 |
| CFRA | Garrett Nelson | $111 | $99.01 | -55.0% | Jun 11, 2024 |
| Robert W. Baird | Eric Coldwell | $129 | $94.75 | -47.7% | May 29, 2024 |
| Argus Research | David Toung | $115 | $97.43 | -53.3% | May 15, 2024 |
| Robert W. Baird | Eric Coldwell | $128 | $102.98 | -48.1% | May 3, 2024 |
| Robert W. Baird | Eric Coldwell | $134 | $110.12 | -45.6% | Apr 5, 2024 |
| Morgan Stanley | Erin Wright | $90 | $92.99 | -63.5% | Aug 15, 2023 |
| Wolfe Research | Tim Anderson | $127 | $79.18 | -48.5% | Apr 12, 2023 |
| Robert W. Baird | Baird Baird | $94 | $78.61 | -61.9% | Feb 8, 2023 |
| Credit Suisse | Analyst unavailable | $92 | $80.14 | -62.7% | Feb 3, 2023 |
| Morgan Stanley | Analyst unavailable | $86 | $78.12 | -65.1% | Jan 6, 2023 |
| Credit Suisse | Analyst unavailable | $79 | $79.22 | -67.9% | Nov 22, 2022 |
| UBS | Analyst unavailable | $78 | $68.51 | -68.4% | Aug 29, 2022 |
| Evercore ISI | Elizabeth Anderson | $68 | $55.83 | -72.4% | May 20, 2022 |
| Deutsche Bank | George Hill | $51 | $58.27 | -79.3% | May 8, 2022 |
| Morgan Stanley | Ricky Goldwasser | $74 | $62.96 | -70.0% | Apr 16, 2022 |
| Barclays | Steve Valiquette | $63 | $53.09 | -74.4% | Jan 17, 2022 |
| UBS | Kevin Caliendo | $61 | $48.84 | -75.2% | Nov 17, 2021 |
| Cowen & Co. | Charles Rhyee | $53 | $50.28 | -78.5% | Aug 11, 2021 |
| Bank of America Securities | Michael Cherny | $56 | $49.2 | -77.3% | Aug 5, 2021 |
Track every rating change on CAH the moment it posts. Free to start.
Start freeGet the CAH recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.